Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25898419 | 0.98 | CYP2D6 (0.34) | CYP2D6CYP1A2CYP2C19CYP2C9TSHR | |
| SCHEMBL25898416 | 0.87 | NUDT1 (0.34) | CYP2D6CYP1A2CYP2C19CYP2C9TSHR | |
| SCHEMBL25898411 | 0.85 | PRKCE (0.39) | CYP2C19CYP2C9TSHRHSD17B10 | |
| SCHEMBL25898417 | 0.84 | NUDT1 (0.36) | CYP2D6CYP1A2CYP2C19CYP2C9TSHR | |
| SCHEMBL25898431 | 0.84 | CYP2D6 (0.49) | CYP2D6CYP1A2CYP2C19CYP2C9TSHR | |
| SCHEMBL15803968 | 0.82 | NUDT1 (0.42) | CYP2D6CYP1A2CYP2C19CYP2C9TSHR | |
| SCHEMBL25898433 | 0.81 | CYP2D6 (0.46) | CYP2D6CYP1A2CYP2C19CYP2C9TSHR | |
| SCHEMBL25898413 | 0.81 | PRKCE (0.36) | CYP2D6CYP1A2CYP2C19CYP2C9TSHR | |
| SCHEMBL19600589 | 0.80 | NUDT1 (0.39) | NUDT1BACE1CNR1HTR2APTGDR2 | |
| SCHEMBL16850508 | 0.80 | NUDT1 (0.39) | NUDT1BACE1CNR1HTR2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234905-A1 | NOVEL TRISPHENOL DERIVATIVE | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2023-07-27 | — | — | US | disclosed |
| US-20230234905-A1 | NOVEL TRISPHENOL DERIVATIVE | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234905-A1 | NOVEL TRISPHENOL DERIVATIVE | TTPA, CDK2AP2, CDKL2 | CYP2D6 1018/4885CYP1A2 243/4885CYP2C19 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.